Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3041% below fair value
$1.00−0.02 (-1.96%)
Close on Nov 12, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Spero Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -67.3%. For fiscal 2025 it was 9.5%, against -152.9% the year before. The highest annual figure on record is 20.7% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.5% | +162.4 |
| FY2024 | Dec 31, 2024 | -152.9% | −173.6 |
| FY2023 | Dec 31, 2023 | 20.7% | +99.6 |
| FY2022 | Dec 31, 2022 | -78.9% | +403.0 |
| FY2021 | Dec 31, 2021 | -481.9% | +366.1 |
| FY2020 | Dec 31, 2020 | -847.9% | −499.6 |
| FY2019 | Dec 31, 2019 | -348.4% | +731.0 |
| FY2018 | Dec 31, 2018 | -1079.3% | +1029.3 |
| FY2017 | Dec 31, 2017 | -2108.6% | +7808.1 |
| FY2016 | Dec 31, 2016 | -9916.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -2921.7% | −2670.9 |
| Q4 FY2025 | Dec 31, 2025 | 76.0% | +220.5 |
| Q3 FY2025 | Sep 30, 2025 | -145.5% | −7.4 |
| Q2 FY2025 | Jun 30, 2025 | -17.2% | +169.7 |
| Q1 FY2025 | Mar 31, 2025 | -250.8% | −99.9 |
| Q4 FY2024 | Dec 31, 2024 | -144.4% | −213.1 |
| Q3 FY2024 | Sep 30, 2024 | -138.0% | −130.5 |
| Q2 FY2024 | Jun 30, 2024 | -186.9% | +287.7 |
| Q1 FY2024 | Mar 31, 2024 | -150.9% | +536.7 |
| Q4 FY2023 | Dec 31, 2023 | 68.7% | +14.1 |
| Q3 FY2023 | Sep 30, 2023 | -7.6% | +582.3 |
| Q2 FY2023 | Jun 30, 2023 | -474.6% | +834.0 |
| Q1 FY2023 | Mar 31, 2023 | -687.6% | +772.4 |
| Q4 FY2022 | Dec 31, 2022 | 54.6% | +1056.9 |
| Q3 FY2022 | Sep 30, 2022 | -589.9% | +145.2 |
| Q2 FY2022 | Jun 30, 2022 | -1308.6% | −948.4 |
| Q1 FY2022 | Mar 31, 2022 | -1460.0% | −1194.2 |
| Q4 FY2021 | Dec 31, 2021 | -1002.3% | −16.6 |
| Q3 FY2021 | Sep 30, 2021 | -735.1% | −259.0 |
| Q2 FY2021 | Jun 30, 2021 | -360.2% | +709.7 |
| Q1 FY2021 | Mar 31, 2021 | -265.8% | +1075.8 |
| Q4 FY2020 | Dec 31, 2020 | -985.6% | +2733.2 |
| Q3 FY2020 | Sep 30, 2020 | -476.1% | −88.7 |
| Q2 FY2020 | Jun 30, 2020 | -1069.8% | −436.6 |
| Q1 FY2020 | Mar 31, 2020 | -1341.6% | −1267.8 |
| Q4 FY2019 | Dec 31, 2019 | -3718.8% | −3063.7 |
| Q3 FY2019 | Sep 30, 2019 | -387.4% | +1274.5 |
| Q2 FY2019 | Jun 30, 2019 | -633.2% | +1520.4 |
| Q1 FY2019 | Mar 31, 2019 | -73.8% | +864.3 |
| Q4 FY2018 | Dec 31, 2018 | -655.1% | +754.8 |
| Q3 FY2018 | Sep 30, 2018 | -1661.9% | +7.5 |
| Q2 FY2018 | Jun 30, 2018 | -2153.6% | +1928.8 |
| Q1 FY2018 | Mar 31, 2018 | -938.1% | +4489.8 |
| Q4 FY2017 | Dec 31, 2017 | -1409.9% | – |
| Q3 FY2017 | Sep 30, 2017 | -1669.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -4082.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -5427.9% | – |
See a number that looks wrong?